Prs16 an Economic Evaluation of a Pharmacological Intervention Using Varenicline as Therapy for Smoking Cessation

Narváez, Javier; Alvis, Nelson; Hoz, Fernando de la; Orozco, John; Porras, Arturo G.

doi:10.1016/s1098-3015(10)73679-2

Cited by 3 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In these analyses, varenicline consistently dominated (i.e. was more effective and less costly) bupropion SR [20][21][22][23][24][25][26][27][28][29][30][31] and nicotine replacement therapy, [20][21][22][23][24][25][26][27][28]30,[32][33][34] was cost effective versus nortriptyline [22] and was dominant or cost effective versus brief counselling [21,24] or unaided cessation, [20][21][22][23][24][25]27,28,30,31] with regard to the cost per quality-adjusted life-year (QALY) and/or life-year gained. Varenicline was also associated with acceptable incremental costs per QALY gained versus bupropion SR in a Swedish costutility analysis that included indirect costs.…”

Section: Pharmacoeconomic Analyses Of Vareniclinementioning

confidence: 96%

“…[20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36] The BENESCO model was used to project future gains in health and healthcare cost savings as a result of a one-time quit attempt with varenicline versus those associated with other smoking cessation interventions. The model used long-term time horizons and 52-week quit rates based on the results of head-to-head trials and other literature sources.…”

Section: Pharmacoeconomic Analyses Of Vareniclinementioning

confidence: 99%

“…Results of analyses using this model, and conducted from the perspective of the healthcare payer in various countries (including the US, [20] Hong Kong [30] and European [21,22,[24][25][26][27][28][29]31,32,34] and Latin American [23,33] countries), predicted that the cost of 12 weeks' smoking cessation therapy with varenicline is offset by direct savings associated with the reduction in smoking-related diseases. In these analyses, varenicline consistently dominated (i.e.…”

Section: Pharmacoeconomic Analyses Of Vareniclinementioning

confidence: 99%

See 2 more Smart Citations

Pharmacoeconomic Spotlight on Varenicline as an Aid to Smoking Cessation†

Keating

Lyseng‐Williamson

2010

CNS Drugs

View full text Add to dashboard Cite

Varenicline (Chantix, Champix) is an orally administered alpha4beta2 nicotinic acetylcholine receptor partial agonist that is indicated as an aid to smoking cessation. Varenicline was an effective aid to smoking cessation and was generally well tolerated in clinical trials, although more data are needed regarding the potential for neuropsychiatric events. The costs associated with varenicline are offset by direct savings associated with the reduction in smoking-related diseases. Indeed, despite their limitations, available pharmacoeconomic analyses from numerous countries support the use of varenicline for 12 or 24 weeks as a cost-effective treatment relative to other smoking cessation therapies in smokers who wish to quit smoking. For example, in modelled cost-effectiveness analyses conducted from a healthcare payer perspective, 12 weeks' treatment with varenicline consistently dominated bupropion sustained release and nicotine replacement therapy, and was dominant over, or considered cost effective relative to, unaided cessation, brief counselling or nortriptyline, with regard to the incremental costs per quality-adjusted life-year or life-year gained.

show abstract

Section: Pharmacoeconomic Analyses Of Vareniclinementioning

confidence: 96%

Section: Pharmacoeconomic Analyses Of Vareniclinementioning

confidence: 99%

Section: Pharmacoeconomic Analyses Of Vareniclinementioning

confidence: 99%

See 1 more Smart Citation

Pharmacoeconomic Spotlight on Varenicline as an Aid to Smoking Cessation†

Keating

Lyseng‐Williamson

2010

CNS Drugs

View full text Add to dashboard Cite

show abstract

“…Cost-effectiveness analyses were based on Markov models, [35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53] most commonly the Benefits of Smoking Cessation on Outcomes (BENESCO) model, [35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51] or a decision-analytic model. [54] The core BENESCO analysis was conducted in the US, [39] with country-specific adaptations subsequently conducted in European [35][36][37][38]41,[44][45][46][47][48][49][50] an...…”

Section: Cost-effectiveness Analysesmentioning

confidence: 99%

“…[51] Analyses using alternative Markov models were conducted in Japan [52] and Korea, [53] and the decision-analytic model was conducted in the US. [54] Varenicline was compared with various other interventions including bupropion SR, [35][36][37][38][39][40][41][43][44][45][46][47]51,54] nicotine replacement therapy, [35,[37][38][39][40][42][43][44][45][46][47][48][49]51,53,54] regular brief counselling alone, [35,44,52] nortriptyline, [38] unaided cessation (i.e. no pharmacological therapy or counselling) [35,[37][38][39][40][41]43,44,46,47,51,…”

Section: Cost-effectiveness Analysesmentioning

confidence: 99%

Varenicline

Keating

Lyseng‐Williamson²

2010

PharmacoEconomics

View full text Add to dashboard Cite

Varenicline (Chantix, Champix) is an orally administered alpha4beta2 nicotinic acetylcholine receptor partial agonist that is indicated as an aid to smoking cessation. Well designed clinical trials indicate that varenicline is an effective aid to smoking cessation. During the last 4 weeks of treatment, carbon monoxide-confirmed continuous abstinence rates were generally significantly higher with varenicline than with placebo, bupropion sustained release (SR) or nicotine replacement therapy. Varenicline also reduced cravings, the reinforcing effects of smoking and some withdrawal symptoms. Another well designed trial demonstrated that extending varenicline therapy by an additional 12 weeks helped maintain abstinence in individuals who had quit smoking. Varenicline was generally well tolerated in clinical trials; nausea, the most commonly occurring adverse event, diminished over time. More data are needed regarding the potential for neuropsychiatric events in varenicline recipients. Some of these events may be associated with nicotine withdrawal, rather than varenicline, although neuropsychiatric events have been observed in individuals who continued to smoke whilst receiving varenicline. In modelled cost-effectiveness analyses based on data from clinical trials in participants receiving smoking cessation therapy, 12 weeks' treatment with varenicline was predicted to be cost effective from a healthcare payer perspective in numerous countries. With regard to the incremental costs per QALY or life-year gained, 12 weeks' treatment with varenicline consistently dominated bupropion SR and nicotine replacement therapy and was dominant over or considered cost effective relative to unaided cessation, regular brief counselling or nortriptyline in analyses based on Markov models. In additional modelled analyses from a healthcare payer perspective, administering varenicline for an additional 12 weeks in participants who had successfully quit smoking was estimated to have acceptable incremental costs per QALY gained relative to varenicline for 12 weeks and to dominate other smoking cessation options. Moreover, in Swedish analyses that also included societal costs for production and consumption, the incremental cost per QALY gained for varenicline versus bupropion SR, and for an additional 12 weeks of varenicline therapy versus varenicline for 12 weeks only, was below commonly accepted thresholds of cost effectiveness. A US decision-analytic model from the perspective of various US health insurance plans demonstrated that, after 2 years, varenicline was predicted to dominate bupropion SR, in terms of the incremental cost per additional smoking cessation. Varenicline was also dominant or cost effective versus nicotine replacement therapy, and cost effective versus unaided cessation. Sensitivity analyses demonstrated that the results of cost-effectiveness studies were generally robust to plausible variations in key parameters. In conclusion, varenicline is an effective aid to smoking cessation. Varenicline was generally well tole...

show abstract